Compare Ascendis Pharma A/S (ASND) vs FirstEnergy Corp. (FE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs FirstEnergy Corp. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while FirstEnergy Corp. trades at $47.92 (market cap $27.72B). The key difference: FirstEnergy Corp. is the larger of the two by market cap, and FirstEnergy Corp. pays a 3.88% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | FE | |
|---|---|---|
Market Cap | $17.74B | $27.72B |
Sector | Health | Utilities |
52-Week High | $277.18 | $51.91 |
52-Week Low | $163.32 | $40.30 |
Enterprise Value | $18.11B | $55.73B |
Dividend Yield | — | 3.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
FirstEnergy (FE) trades at $47.92, up 0.61% with neutral technical signals. The company shows steady revenue growth to $15.09B in 2025 and a net income margin of 6.86%, though cash flow remains negative. Recent news highlights opportunities from surging data center demand and a $36B investment plan for grid upgrades. Analyst consensus is mixed with a $52 price target, indicating potential upside from current levels.
Outlook is cautiously optimistic given FE's strategic investments and data center tailwinds, but risks include regulatory uncertainty and high debt levels. The stock presents a balanced opportunity for investors seeking utility exposure with growth potential, though monitoring earnings execution and capex efficiency is crucial for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →
